Drugs / EGFR FPBMC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06479239 | Nov 2024 → Dec 2027 expected | malignant pancreatic neoplasm | University of Virginia | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EGFR FPBMC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06479239 ↗ |
| Modality | Cell therapy | “the mononuclear cells are reinfused into the patients” NCT06479239 ↗ |
| Route | Intravenous | “by intravenous infusion” NCT06479239 ↗ |
| Target | EGFR | “anti-Epidermal Growth Factor Receptor (EGFR)” NCT06479239 ↗ |